Opendata, web and dolomites

CYPNASH SIGNED

Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CYPNASH project word cloud

Explore the words cloud of the CYPNASH project. It provides you a very rough idea of what is the project "CYPNASH" about.

industry       therapy    permeability    non    vivo    macrocyclic    unexplored    modulation    basis    healthcare    stg    pursued    small    animal    data    selectivity    peptidic    agents    pursuing    assembling    transition    poc    company    validate    maximize    pharmaceutical    medical    alcoholic    cellular    platform    pharmacological    preclinical    absence    inhibit    triple    team    assembles    structurally    optimize    pk    previously    suitable    form    undertaken    computational    dmpk    erc    mode    approved    protein    treating    vitro    compelling    clinical    trials    family    models    prevalent    follow    licensing    binding    designed    pocket    decade    pore    programs    biological    physical    cyclophilins    disease    molecules    innovative    damage    orally    discovery    actions    efficacy    liver    population    cells    steatohepatitis    business    scientists    consultation    asset    mechanism    cyclophilin    compound    drug    delivering    discovered    mitochondrial    ebdd    scaffolds    basic    selective    chronic    inhibitors    unmet    nash    executives    bioavailable    sub    fibrosis    candidate    biophysical    valuable    partnering    treatments    optimisation    inhibition   

Project "CYPNASH" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF EDINBURGH 

Organization address
address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL
website: www.ed.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 150˙000.00

Map

 Project objective

Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent chronic liver disease (3-4% of the US population) for which there is currently no approved drug therapy. In the absence of innovative treatments healthcare costs associated with this disease are set to triple over the next decade. To address this unmet medical need, the pharmaceutical industry is currently pursuing a range of liver fibrosis drug discovery programs based on different mode of actions. A compelling mechanism for treating liver damage is pharmacological modulation of the mitochondrial permeability transition pore in liver cells via inhibition of the protein cyclophilin D. However existing cyclophilin inhibitors based on peptidic macrocyclic scaffolds are challenging to optimize into sub-type selective orally bioavailable agents suitable for clinical trials of liver fibrosis.

As part of basic research activities undertaken during ERC StG EBDD to validate a computational-biophysical drug discovery platform, we have discovered a structurally novel family of small molecules that inhibit cyclophilins by targeting a previously unexplored binding pocket. The objective of this POC is to identify a lead compound in this family with potential for development towards a NASH clinical candidate. Such a candidate will form the basis of follow-on lead optimisation programs pursued via partnering or out-licensing with a pharmaceutical partner. The activities of this POC will focus on assembling a data package of in vitro DMPK, in vivo PK, in vitro sub-type selectivity and in vitro and in vivo efficacy measurements in relevant cellular and animal models of liver fibrosis. This POC has been designed in consultation with a major pharmaceutical company and assembles a team of physical and biological scientists and business development executives to maximize the likelihood of delivering a valuable preclinical NASH asset.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYPNASH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYPNASH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TransTempoFold (2019)

A need for speed: mechanisms to coordinate protein synthesis and folding in metazoans

Read More  

TOROS (2019)

A Theory-Oriented Real-Time Operating System for Temporally Sound Cyber-Physical Systems

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  
lastchecktime (2022-12-02 17:25:36) correctly updated